Need for estradiol assays with a lower functional sensitivity in clinical studies examining postmenopausal women treated with aromatase inhibitors

Journal of Clinical Oncology

Volumn 31, Issue 4, 2013, Pages 509-

  Pauwels, Steven ^a   Lintermans, Anneleen ^a   Neven, Patrick ^a   Verhaeghe, Johan ^a   Jans, Ivo ^a   Billen, Jaak ^a   Vanderschueren, Dirk ^a   Vermeersch, Pieter ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; ESTRADIOL; ESTRONE SULFATE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESTROGEN; NITRILE; TRIAZOLE DERIVATIVE;

BODY MASS; ESTRADIOL BLOOD LEVEL; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; HUMAN; LETTER; LIMIT OF QUANTITATION; POSTMENOPAUSE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; BLOOD; BREAST TUMOR; FEMALE; NEOPLASM; NOTE;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BODY MASS INDEX; BREAST NEOPLASMS; ESTROGENS; FEMALE; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; NITRILES; TRIAZOLES;

EID: 84874782120     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.46.2622     Document Type: Letter

References (7)

1. Folkerd EJ, Dixon JM, Renshaw L, et al: Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer. J Clin Oncol 30:2977-2980, 2012
2. Sestak I, Distler W, Forbes JF, et al: Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: An exploratory analysis from the ATAC trial. J Clin Oncol 28:3411-3415, 2010
3. Pfeiler G, Königsberg R, Fesl C, et al: Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: An analysis of the prospective ABCSG-12 trial. J Clin Oncol 29:2653-2659, 2011
4. Pfeiler G, Stöger H, Fesl C, et al: Impact of body mass index on the efficacy of endocrine therapy in postmenopausal breast cancer patients: An analysis of the ABCSG 6 and 6a trial. Presented at San Antonio Breast Cancer Symposium, December 8-12, 2010, San Antonio, TX (abstr SABCS10-PD09-05)
5. Dixon JM, Renshaw L, Young O, et al: Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer. J Clin Oncol 26:1671-1676, 2008
6. Clinical and Laboratory Standards Institute: Evaluation of detection capability for clinical laboratory measurement procedures: Approved guideline - EP17-A2 (ed 2). Wayne, PA, Clinical and Laboratory Standards Institute, 2012
7. Armbruster DA, Pry T: Limit of blank, limit of detection and limit of quantitation. Clin Biochem Rev 29:S49-S52, 2008